Jamie Braden
Primary Care · Flint, MINPI 1053882209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,583, 4.5 times the $355 reported in 2021. Among primary care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$940
- GSK$667
- Vanda Pharmaceuticals Inc.$435
- Sumitomo Pharma America, Inc.$417
- Nestle Healthcare Nutrition Inc.$242
- plus $982 from 18 others
What the payments were for
- Food & beverage$4,749100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $1,067 |
| Otsuka America Pharmaceutical, Inc. | 36 | $940 |
| GSK | 14 | $667 |
| Vanda Pharmaceuticals Inc. | 21 | $435 |
| Sumitomo Pharma America, Inc. | 15 | $417 |
| Nestle Healthcare Nutrition Inc. | 7 | $242 |
| Intra-sana Laboratories | 3 | $135 |
| Amgen | 7 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $117 |
| Johnson & Johnson | 1 | $86 |
| Axsome Therapeutics, Inc. | 5 | $82 |
| Novo Nordisk | 4 | $67 |
| Lundbeck LLC | 3 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $57 |
| Alkermes, Inc. | 2 | $47 |
| Lilly USA, LLC | 3 | $43 |
| Novartis | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| AstraZeneca | 1 | $14 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$245
- Fanapt$240
- ZENPEP$125
- Reltone 200 Mg$124
- GLYCATE$124
- Reltone 400 Mg$124
- NURTEC ODT$110
- GEMTESA$109
How this compares
$4,749 in reported general payments places this provider in the 90th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $61,099 |
| TrulicityDulaglutide | 33 | $30,367 |
| MounjaroTirzepatide | 28 | $27,825 |
| JardianceEmpagliflozin | 30 | $25,405 |
| EliquisApixaban | 25 | $22,711 |
| WegovySemaglutide | 12 | $15,808 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 173 | $6,004 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $5,189 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,856 |
| Novolog FlexpenInsulin Aspart | 22 | $2,903 |
| Ventolin HfaAlbuterol Sulfate | 46 | $2,588 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,576 |
| Atorvastatin Calcium | 250 | $2,168 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $1,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $67 | $76,90776 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $43 | $58,19261 claims |
| PfizerEliquis | $19 | $22,71125 claims |
| GSKTrelegy Ellipta | $667 | $14,22221 claims |
| AstraZenecaSymbicort | $14 | $4,85621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 primary care providers in Michigan.
Other primary care in Flint
- Amorena TompkinsFlint$2K
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.